Default: Drug Safety

ISSN: 0114-5916

Journal Home

Journal Guideline

Drug Safety Q1 Unclaimed

Adis International Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drug Safety is a journal indexed in SJR in Pharmacology and Toxicology with an H index of 124. It has a price of 3290 €. It has an SJR impact factor of 1,377 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,377.

Drug Safety focuses its scope in these topics and keywords: drug, adverse, safety, surveillance, events, media, medicines, reactions, current, social, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

3290 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Drug Safety

1,377

SJR Impact factor

124

H Index

127

Total Docs (Last Year)

373

Total Docs (3 years)

5207

Total Refs

1399

Total Cites (3 years)

314

Citable Docs (3 years)

3,98

Cites/Doc (2 years)

41

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


drug, adverse, safety, surveillance, events, media, medicines, reactions, current, social, pharmacovigilance, data, event, evaluation, crosssectional, economic, action, defects, analysisfatal, countriesa, control, comparison, clinicaltrialsgov, clinical, active, case, birth, awareness, assessing,



Best articles by citations

Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950-2012

View more

Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain

View more

ISoP Fellowships: Recognising Contributions to the Goals of ISoP

View more

Detecting Medication Errors in the New Zealand Pharmacovigilance Database

View more

Comment on: "Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries"

View more

Memantine for the Treatment of Alzheimer???s Disease

View more

Safety of Agents Used to Prevent Mother-to-Child Transmission of HIV

View more

Therapeutic Risk Management of Medicines

View more

Lipodystrophy Syndrome in HIV Infection

View more

Comment on: "Pharmacovigilance in the Middle East"

View more

Comment on: "Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance"

View more

Prevention and Management of Extravasation of Cytotoxic Drugs

View more
SHOW MORE ARTICLES

Drug Safety Issues in Pregnancy Following Transplantation and Immunosuppression

View more

Distinguishing Hazards and Harms, Adverse Drug Effects and Adverse Drug Reactions

View more

Authors' Reply to Ahmad SR: "Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries"

View more

A Comparison of the Empirical Performance of Methods for a Risk Identification System

View more

Comment on: Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals Analysis of Trends in Dispensing Patterns in The Netherlands from 1998 to 2008

View more

Carbapenems in Serious Infections

View more

A Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database

View more

Authors' Reply to Harpaz et al. Comment on: "Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance"

View more

Empirical Performance of the Calibrated Self-Controlled Cohort Analysis Within Temporal Pattern Discovery: Lessons for Developing a Risk Identification and Analysis System

View more

Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury

View more

Adverse Drug Reaction Reporting in the UK

View more

Labelling and ???Dear Doctor??? Letters

View more

FAQS